We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Routine Genetic Testing Benefits Patients with Advanced Inherited Heart Muscle Disease

By LabMedica International staff writers
Posted on 01 Sep 2023

Dilated cardiomyopathy (DCM) is a condition where the heart muscle weakens, causing the heart to enlarge and reducing its ability to effectively pump blood throughout the body. More...

It can develop at any age but is more common around the mid-40s. Symptoms include shortness of breath, fatigue, swollen legs and feet, and irregular heartbeat. In severe cases, it can lead to heart failure or sudden cardiac death due to abnormal heart rhythms. Genetic testing is a crucial tool to identify gene mutations that can cause inherited heart conditions like cardiomyopathy. Despite the knowledge that DCM often runs in families, genetic testing is seldom conducted on patients who have undergone heart transplants or received a left ventricular assist device (LVAD), a mechanical heart pump. Now, a multi-site, five-year study has demonstrated the benefits of routine genetic testing for patients with advanced disease from DCM and their at-risk family members.

The DCM Precision Medicine Study, led by researchers at MedStar Health (Columbia, MD, USA) and colleagues from across the U.S., investigated clinical and genetic data from 1,265 patients across 25 top academic heart failure and transplant programs in the U.S. These programs are part of the Dilated Cardiomyopathy Consortium. The study revealed that DCM patients with advanced heart disease, meaning those who had a heart transplant or an LVAD, were over twice as likely to carry a disease-causing mutation in a relevant DCM gene compared to those without advanced heart disease.

“These study results validate the concept that routine genetic testing performed on these patients allows us to identify their family members who may be at risk of developing DCM and when early signs of disease do appear, we can begin earlier treatment in those family members, perhaps ultimately avoiding the need for either heart transplantation or mechanical circulatory support,” said Mark Hofmeyer, MD, medical director of the Advanced Heart Failure Intermediate Care Unit at MedStar Heart & Vascular institute at MedStar Washington Hospital Center and the first author of the DCM Precision Medicine study.

Related Links:
MedStar Health 


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.